ERBB2 and neoplasm: They concluded that traditional tumor immunotherapy mainly focuses on enhancing immunity by using effector cells/molecules to stimulate the immune system to directly attack tumor cells, which is also called “passive” immunotherapy, such as antibody-targeted therapies (e.g., Her2/neu monoclonal antibody (mAb) [37], anti-EGFR mAb [38] and anti-CD20 mAb) and adoptive immune cell therapies (e.g., macrophage-based adoptive cell therapy [39], chimeric antigen receptor (CAR)-T [40], CAR-NK [41] and adoptive CD8+ T-cell therapy [42]).